EUVIMEDEUVIMED entdecken
Crossref

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association

Ana Barac iD, Avirup Guha iD, Thomas R Fleming, Marc Bonaca iD, Paaladinesh Thavendiranathan iD, Anita Deswal iD, Laleh Amiri-Kordestani iD, Vishal Bhatnagar iD, Raul Cordoba iD, Sara Hurvitz iD, Alex A Adjei, Neeraj Agarwal iD und 1 weitere

Journal of Clinical Oncology · 01.08.2026 · 44 (22) · 2140-2155

DOI: 10.1200/jco-25-01647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.08.2026. Verfasst von Ana Barac und 12 weiteren Autor:innen. Beteiligte Einrichtung: INOVA Heart and Vascular Institute, Fairfax, VA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Endpoint Determination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The unprecedented expansion of approved oncology therapies has prolonged survival and transformed the prognosis for many patients diagnosed with cancer. However, cancer treatments may be associated with cardiovascular toxicities that manifest through vascular, myocardial, or metabolic pathways, potentially limiting the use of cancer therapeutics and adversely affecting outcomes. Oncology clinical trials provide an important opportunity to evaluate cardiovascular safety signals by generating data on the incidence, timing, and spectrum of toxicities. However, progress has been limited by inconsistent definitions and variable approaches to event characterization. This scientific statement aligns the advances in cardiovascular medicine and cardiovascular clinical trials to provide criteria for systematic selection, rigorous characterization, and adjudication of cardiovascular endpoints in contemporary oncology trials. The proposed framework links drug-specific mechanisms to endpoint selection and standardizes the approach to definitions of adverse cardiovascular events, including heart failure, arrhythmias, myocarditis, and thrombotic events. Definitions of major adverse cardiac events, clinical events, and surrogate endpoints are discussed, along with strategies for alignment with the Common Terminology Criteria for Adverse Events and patient-reported outcomes. Practical guidance is provided for prospective surveillance, decentralized and hybrid clinical trial designs, independent endpoint adjudication, and statistical approaches to competing risks and late-emerging toxicities. By harmonizing cardiovascular endpoint assessment across oncology trials, this scientific statement aims to enhance risk stratification, facilitate regulatory acceptance, and inform clinical decision making, ultimately improving patient safety while supporting innovation in cancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCardiovascular DiseasesClinical Trials as TopicEndpoint DeterminationNeoplasmsHumansAmerican Heart AssociationCardiotoxicityUnited States

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • INOVA Heart and Vascular Institute, Fairfax, VA.
  • Augusta University, Augusta, GA.
  • University of Washington, Hans Rosling Center for Population Health, Seattle, WA.
  • University of Colorado School of Medicine, Denver, CO.
  • Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
  • University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Ana Barac, Avirup Guha, Marc Bonaca, Paaladinesh Thavendiranathan, Anita Deswal, Laleh Amiri-Kordestani, Vishal Bhatnagar, Raul Cordoba, Sara Hurvitz, Neeraj Agarwal

Zitieren

APA

Barac, A., Guha, A., Fleming, T. R., Bonaca, M., Thavendiranathan, P., Deswal, A., Amiri-Kordestani, L., Bhatnagar, V., Cordoba, R., Hurvitz, S., Adjei, A. A., Agarwal, N., & American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; Council on Cardiovasc… (2026). Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Journal of Clinical Oncology, 44(22), 2140-2155. https://doi.org/10.1200/jco-25-01647

Vancouver

Barac A, Guha A, Fleming TR, Bonaca M, Thavendiranathan P, Deswal A, et al. Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Journal of Clinical Oncology. 2026;44(22):2140-2155. doi:10.1200/jco-25-01647

BibTeX
@article{Barac2026,
  author = {Barac, Ana and Guha, Avirup and Fleming, Thomas R and Bonaca, Marc and Thavendiranathan, Paaladinesh and Deswal, Anita and Amiri-Kordestani, Laleh and Bhatnagar, Vishal and Cordoba, Raul and Hurvitz, Sara and Adjei, Alex A and Agarwal, Neeraj and American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; Council on Cardiovasc…, American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; Council on Cardiovasc…},
  title = {Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {22},
  pages = {2140--2155},
  doi = {10.1200/jco-25-01647}
}
Kostenlos starten →